Cargando…

Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells

Members of the bromodomain and extra-C terminal (BET) domain protein family and the histone deacetylase (HDAC) enzyme family regulate the expression of important oncogenes and tumor suppressor genes. Here we show that the BET inhibitor JQ1 inhibits proliferation and induces apoptosis of both triple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borbely, Gabor, Haldosen, Lars-Arne, Dahlman-Wright, Karin, Zhao, Chunyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741790/ https://www.ncbi.nlm.nih.gov/pubmed/26378038

Ejemplares similares

Estrogen receptor β2 induces proliferation and invasiveness of triple negative breast cancer cells: association with regulation of PHD3 and HIF-1α
por: Bialesova, Lucia, et al.
Publicado: (2017)

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
por: Heinemann, Anja, et al.
Publicado: (2015)

Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting
por: Nevi, Lorenzo, et al.
Publicado: (2023)

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma
por: Gusyatiner, Olga, et al.
Publicado: (2021)

Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression
por: Williams, Cecilia, et al.
Publicado: (2009)

Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
por: Yao, Zhicheng, et al.
Publicado: (2022)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies
por: Burmeister, Aaron, et al.
Publicado: (2022)

Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor
por: Chiu, Chang-Fang, et al.
Publicado: (2019)

Expression of the three components of linear ubiquitin assembly complex in breast cancer
por: Kharman-Biz, Amirhossein, et al.
Publicado: (2018)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
por: Hölscher, Alexander S., et al.
Publicado: (2018)

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
por: Manzotti, Gloria, et al.
Publicado: (2019)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells
por: Cortiguera, María G., et al.
Publicado: (2019)

Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
por: Kang, Sun Kyoung, et al.
Publicado: (2020)

17 big bets for a better world
por: Tackmann, Stig, et al.
Publicado: (2016)

p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells
por: Zhuang, Ting, et al.
Publicado: (2015)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity
por: Lindberg, Karolina, et al.
Publicado: (2011)

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
por: Shu, Shaokun, et al.
Publicado: (2016)

Induction of autophagy does not alter the anti-tumor effects of HDAC inhibitors
por: Newbold, A, et al.
Publicado: (2012)

High-Throughput Screening for CEBPD-Modulating Compounds in THP-1-Derived Reporter Macrophages Identifies Anti-Inflammatory HDAC and BET Inhibitors
por: Ullmann, Tatjana, et al.
Publicado: (2021)

USP17 is required for peripheral trafficking of lysosomes
por: Lin, Jia, et al.
Publicado: (2022)

Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma
por: Zhang, Yaqin, et al.
Publicado: (2017)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Expression of activator protein-1 (AP-1) family members in breast cancer
por: Kharman-Biz, Amirhossein, et al.
Publicado: (2013)

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
por: Nakashima, Hiroshi, et al.
Publicado: (2015)

USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3
por: Zhan, Wei, et al.
Publicado: (2020)

Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine
por: Zhang, Xiaohong Mary, et al.
Publicado: (2016)

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
por: Kim, Sa Rang, et al.
Publicado: (2018)

Design and Characterization of Bivalent BET Inhibitors
por: Tanaka, Minoru, et al.
Publicado: (2016)

Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
por: Wang, Wenyu, et al.
Publicado: (2021)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair
por: Huan, Songwei, et al.
Publicado: (2020)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ecoti491btvtu1ogqqd5prlp0u